Concurrently, Tan et al. observed significant overall survival benefits with: T0–T4 cancers, all sites of (single or multiple) metastases, patients with/without radiation treatment and patients with hormone receptor positive/negative disease when LRT was administered. The gene discussed is NR4A1; the disease is cancer.